TOXINS2026:ClinicalUpdatesonGalderma’sLeadingNeuromodulatorPortfolioFurtherReinforceItsLeadershipinInjectableAesthetics
===2026/1/14 14:24:31===
– the first and only ready-to-use liquid neuromodulator designed with PEARL Technology – and Dysport. Additionally, Galderma will be hosting a Relfydess Masterclass in which expert speakers will delve into the science and clinical data behind Relfydess.
“At TOXINS 2026, we will demonstrate our continued leadership in neuromodulation through updates on our leading portfolio, and an educational session on Relfydess, an innovative, science-backed neuromodulator that delivers advanced performance. As the only company with a portfolio of neuromodulators, we’re building on our heritage in the space by developing next-generation solutions that address the evolving expectations of both patients and practitioners.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA
=*=*=*=*=*=
当前为第2/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页